Eupraxia Pharmaceuticals Inc.

About Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company focused on developing targeted therapies using a proprietary extended-release delivery system called Diffusphere™. Their mission is to provide the right dose of a drug in the right place for the right amount of time, aiming to improve treatment outcomes, reduce side effects, and simplify care for patients.

Products & Services

Diffusphere™ Technology:A proprietary drug delivery platform designed for extended-release formulations that target diseased tissues directly, minimizing exposure to the rest of the body, and applicable in inflammatory diseases, oncology, pain, and other conditions.

EP-104GI for Eosinophilic Esophagitis (EoE):A therapy designed to deliver sustained anti-inflammatory treatment directly to the esophagus, aiming to reduce symptoms and tissue damage with fewer doses.

Joint Pain Relief Treatments:Clinical pipeline targeting musculoskeletal diseases, offering potential long-term relief for joint disorders with a single treatment.

Specialties

Extended-release drug delivery Targeted therapies for inflammatory diseases Gastrointestinal and musculoskeletal disease treatments Oncology and pain management solutions

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 63200000 MR: - FA: US$63.2 million FAN: 63200000	D: 2026-02-20 FD: 2026-02-20	4 investors
2	RT: Public Offering T: - FT: Public Offering	A: 55000000 MR: - FA: approximately US$55 million FAN: 55000000	D: 2026-02-19 FD: 2026-02-19	4 investors
3	RT: Public Offering T: - FT: Public Offering	A: 80500000 MR: - FA: US$80.5 million FAN: 80500000	D: 2025-09-24 FD: 2025-09-24	3 investors
4	RT: Public Offering T: - FT: Public Offering	A: 70000000 MR: - FA: US$70 million FAN: 70000000	D: 2025-09-22 FD: 2025-09-22	3 investors
5	RT: Private Placement T: - FT: Private Placement	A: 44528190 MR: - FA: C$44,528,190 FAN: 44528190	D: 2024-10-31 FD: 2024-10-31	-
6	RT: Convertible Debt T: - FT: Convertible Debt	A: 12000000 MR: - FA: C$12 million FAN: 12000000	D: 2024-08-02 FD: 2024-08-02	2 investors
7	RT: Convertible Debt T: - FT: Convertible Debt	A: 8700000 MR: - FA: C$12 million FAN: 8700000	D: 2024-08-02 FD: 2024-08-02	2 investors
8	RT: Public Offering T: - FT: Public Offering	A: 25400838 MR: - FA: C$33,867,784 FAN: 25400838	D: 2024-03-15 FD: 2024-03-15	1 investors
9	RT: Marketed Public Offering T: - FT: Marketed Public Offering	A: 22200000 MR: - FA: C$30 million FAN: 22200000	D: 2024-03-12 FD: 2024-03-12	1 investors
10	RT: Public Offering T: - FT: Public Offering	A: 30000000 MR: - FA: approximately $30 million FAN: 30000000	D: 2024-03-11 FD: 2024-03-11	1 investors
11	RT: Non-Brokered Private Placement T: - FT: Non-Brokered Private Placement	A: 22287125 MR: - FA: C$22,287,125 FAN: 22287125	D: 2023-08-18 FD: 2023-08-18	-

Public Offering Latest

2026-02-20

$63.2M

4 investors (Pro only)

Public Offering 2026-02-19

$55.0M

Public Offering 2025-09-24

$80.5M

View 10 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Simon Pimstone

Founder and CEO

J

James A. Helliwell

Co-founder and CEO of Eupraxia Pharmaceuticals

R

Richard Glickman

Co-founder, Chairman and Chief Executive Officer

J

Joseph Freedman

Private equity investor and corporate director

J

John Montalbano

Director and Audit Chair

M

Michael Wilmink

Director

View 21 more team members with Pro

Unlock Full Team Directory

Recent News